$3.79
▲ +$0.09
(+2.43%)
Vol 3.0M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.5B
ROE
-75.9%
Margin
-3811.9%
D/E
0.00
Beta
1.67
52W
$1–$7
Wall Street Consensus
20 analysts · Apr 20265
Strong Buy
14
Buy
1
Hold
0
Sell
0
Strong Sell
95.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 40.0%
Next Report
May 11, 2026
EPS Estimate: $-0.11
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.11 | — | — |
| Dec 2025 | $-0.11 | $-0.06 | +$0.05 |
| Sep 2025 | $-0.12 | $-0.28 | $-0.16 |
| Jun 2025 | $-0.12 | $-0.14 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $40K | -$5K | $1.6M | $719K | $749K |
| Net Income | -$26.3M | -$39.0M | -$26.4M | -$27.7M | -$61.1M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -54.7% | -54.7% | -54.7% | -54.7% | -54.7% | -75.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -3856.6% | -3476.5% | -3476.5% | -3476.5% | -3476.5% | -3811.9% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 4.29 | 4.29 | 4.29 | 4.29 | 4.29 | 0.00 |
| Current Ratio | 4.02 | 4.02 | 4.02 | 4.02 | 4.02 | 7.90 |
Key Ratios
ROA (TTM)
-55.3%
P/S (TTM)
491.42
P/B
1.9
EPS (TTM)
$-0.57
CF/Share
$-0.41
Rev Growth 3Y
-75.3%
52W High
$6.75
52W Low
$1.15
$1.15
52-Week Range
$6.75
Financial Health
Free Cash Flow
-$28.6M
Net Debt
-$27.4M
Cash
$30.4M
Total Debt
$3.0M
As of Sep 30, 2025
How does ATAI compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ATAI valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
491.4
▲
9828%
above
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
1.9
▼
9%
below
peers
(2.1)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ATAI profitability vs Pharmaceuticals peers
ROE
-75.9%
▼
40%
below
peers
(-54.3%)
vs Peers
vs Industry
Weak
Net margin
-3811.9%
▼
7947%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-55.3%
▼
48%
below
peers
(-37.4%)
vs Peers
vs Industry
Below avg
ATAI financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
7.9
▲
135%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.7
▲
78%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
ATAI fundamentals radar
ATAI
Peer median
Industry
ATAI profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio